Your Cart is Empty
BUY 1 GET 1 FREE · AUTO APPLIES AT CHECKOUT
**IMPORTANT DISCLAIMER:This article is an educational summary of scientific research published through June 2022. CBD is not approved by the FDA to prevent, treat, cure, or mitigate COVID-19 or any other disease. All studies discussed are preliminary in nature. None of the findings discussed constitute medical advice. Always consult a qualified healthcare professional for COVID-19 prevention and treatment guidance.
The first half of 2022 brought a notable surge in peer-reviewed publications examining cannabidiol (CBD) and its potential interactions with SARS-CoV-2 and COVID-19 pathophysiology. Several papers — including a high-profile study in Science Advances — attracted mainstream media coverage and generated significant public curiosity about whether CBD might have a role in the COVID-19 landscape.
This research roundup fromPureCraft CBD summarizes the most significant studies published through June 2022, contextualizes their findings accurately, and — critically — explains what responsible scientific interpretation requires. We are not in the business of making health claims we cannot support. Our goal is to help you understand what researchers are actually exploring and what the science does and does not say.
The single most-discussed piece of CBD and COVID-19 research published through mid-2022 was a January 2022 study inScience Advances by Nguyen, Yang, et al. from the University of Chicago. This study attracted widespread media coverage and deserves careful examination — both for what it found and what it did not find.
The researchers conducted a series of cell culture (in vitro) experiments examining whether CBD and its metabolite 7-OH-CBD could affect SARS-CoV-2 replication. They also conducted a retrospective analysis of electronic health records from patients prescribed Epidiolex (the FDA-approved pharmaceutical CBD) to examine whether CBD use was associated with lower rates of COVID-19 positive tests.
The authors were explicit in their cautions. They wrote that the findings"should not be taken as a recommendation to use CBD to treat or prevent COVID-19." They noted: the cell culture concentrations required may not be safely achievable in humans; the retrospective EHR analysis could not control for all confounding variables; and the study did not include any randomized clinical trial component. The authors specifically warned against people self-medicating with consumer CBD products based on these findings.
Following the study's publication and the resulting media coverage, the FDA reaffirmed its position: no CBD product is approved to prevent or treat COVID-19, and consumers should not interpret this or any other preliminary study as evidence that CBD products are effective against COVID-19. The FDA has continued to issue warning letters to companies making COVID-19 claims about CBD. Full guidance:FDA.gov.
Multiple preclinical studies published in 2021–2022 continued to explore CBD's effects on the cytokine profiles associated with severe COVID-19. A study by El-Saber Batiha et al. published inFrontiers in Cellular and Infection Microbiology (2021) reviewed the existing evidence for CBD as a potential anti-inflammatory agent in the context of COVID-19, concluding that while the mechanistic rationale was scientifically sound, human clinical evidence remained absent.
These studies consistently identified the same gap: CBD reduces pro-inflammatory cytokine markers in laboratory and animal models, but no clinical trial has tested whether this translates to benefit in human COVID-19 patients.
SARS-CoV-2 enters human cells primarily by binding to ACE2 receptors. A 2021 study published inCannabis and Cannabinoid Research by Wang et al. examined whether hemp-derived CBD extracts affected ACE2 expression in cell models. The researchers found that certain hemp extracts appeared to downregulate ACE2 expression in cell cultures, raising the theoretical possibility that this might affect viral entry.
Critically, this research examinedhemp extracts — not isolated CBD — making it difficult to attribute any findings to CBD specifically. The study also involved cell models only, and the researchers noted the need for extensive further research before any conclusions about human applications could be drawn.
By mid-2022, researchers had begun to propose investigating CBD for long COVID — the persistent, multi-system symptoms experienced by some patients after acute COVID-19 infection. Theoretical rationales included CBD's anti-inflammatory and neuroprotective properties, which are relevant to some long COVID symptom clusters.
As of June 2022, no published clinical trial results existed for CBD and long COVID specifically. This remained an area of investigational interest rather than established research findings.
The National Institutes of Health funded several grants examining cannabinoids and COVID-19 between 2020 and 2022 as part of the Rapid Acceleration of Diagnostics (RADx) and related pandemic response initiatives. NIH funding for a research area reflects scientific interest and plausibility — it does not constitute endorsement of a treatment or confirmation of efficacy.
|
Research Area |
Status as of June 2022 |
Evidence Level |
Supports Treatment Claims? |
|
CBD inhibits SARS-CoV-2 in cell cultures |
Published (Science Advances) |
Preclinical only |
No |
|
CBD reduces COVID-related cytokines |
Multiple preclinical studies |
Preclinical only |
No |
|
CBD and ACE2 expression |
Cell culture studies (hemp extracts) |
Preclinical only |
No |
|
CBD and long COVID |
Proposed; no trial results |
Theoretical only |
No |
|
Retrospective EHR association (Epidiolex) |
Single observational analysis |
Observational / very low |
No |
|
Randomized controlled trial in humans |
None completed |
N/A |
No |
|
FDA approval for COVID-19 |
Not approved |
N/A |
No |
The Science Advances study generated headlines such as "CBD may fight COVID-19" and "Study finds CBD stops coronavirus replication" — framing that significantly overstated the findings and their implications. This pattern — dramatic media framing of preliminary laboratory research — is one of the most persistent problems in science communication.
What the study actually showed was that CBD inhibited SARS-CoV-2 replication in a laboratory cell culture model. The distance between that finding and "CBD fights COVID-19 in humans" is enormous and involves multiple unanswered questions:
None of these questions had been answered by June 2022 — and they are precisely the questions that human clinical trials are designed to answer.
The retrospective EHR component of the Science Advances study examined patients taking Epidiolex — the only FDA-approved CBD medication, used for rare epilepsy syndromes. It is important to understand that Epidiolex is:
The retrospective association observed in Epidiolex patientscannot be directly extrapolated to consumer CBD products. Dosing, bioavailability, and product quality vary enormously across the consumer CBD market — making any direct comparison scientifically invalid.
PureCraft CBD sells hemp-derived CBD products for general wellness purposes. We believe in complete transparency about what our products are — and what they are not. We do not claim, suggest, or imply that any of our products treat, prevent, mitigate, or cure COVID-19 or any other disease. These statements have not been evaluated by the FDA.
We cover this research because our customers deserve to understand the science landscape — accurately and in context — not because we believe current research supports any COVID-19 claims. An informed consumer who understands the difference between a cell culture study and a clinical trial is better equipped to evaluate all health information they encounter.
All of our products undergo rigorous independent laboratory testing. View ourpublished lab results for complete product transparency.
No. The January 2022 Science Advances study showed that CBD inhibited SARS-CoV-2 replication in cell cultures — a laboratory model. The study's own authors explicitly stated this should not be taken as evidence that CBD treats or prevents COVID-19 in humans. No human clinical trial has established this.
The FDA's position has been consistent: no CBD product is approved to prevent, treat, cure, or mitigate COVID-19. The FDA continued issuing warning letters through 2022 to companies making COVID-19 claims about CBD products.
It is a legitimate, peer-reviewed study published in a respected journal. Its findings about CBD and SARS-CoV-2 in cell culture are scientifically interesting. However, the study is appropriately understood as a preclinical finding that raises hypotheses for future research — not as evidence of clinical efficacy in human patients.
CBD has well-documented anti-inflammatory properties in preclinical models. Severe COVID-19 involves a hyperinflammatory response. These facts create a theoretical biological rationale for investigation — but no human clinical trial has tested whether CBD reduces COVID-19-related inflammation in patients or improves outcomes. The question remains open and unanswered.
As of June 2022, a small number of registered clinical trials were exploring cannabinoids in COVID-19 contexts, primarily for symptom management. None had published results. The ClinicalTrials.gov database is the authoritative source for current trial status.
No. The retrospective EHR analysis found an association between Epidiolex use and lower COVID-19 positive test rates in a specific patient population. Associations in retrospective data cannot establish causation — the lower rates could reflect many other factors including differences in patient behavior, comorbidities, or healthcare access. The study authors did not claim this data proves CBD prevents COVID-19.
Follow current evidence-based guidance from theCDC and your healthcare provider. As of mid-2022, COVID-19 vaccination remains the most effective evidence-based prevention strategy, and FDA-authorized antiviral treatments (Paxlovid, remdesivir) are available for eligible individuals who contract the virus.
Yes. Research interest in this area continued beyond June 2022. Future studies — particularly any that advance to human clinical trials — will provide more definitive data. We will continue to cover significant developments in the cannabinoid research space with the same commitment to accurate, contextualized reporting.
Because our customers read the news. When a study generates headlines like "CBD may fight COVID," we believe it is our responsibility to provide accurate context — not to amplify the hype, and not to pretend the research doesn't exist. Health literacy matters, and we are committed to supporting it.
As of June 2022, no national regulatory authority had approved a CBD product specifically for COVID-19 treatment or prevention. Regulatory agencies in the US, EU, UK, Canada, and Australia all maintained positions consistent with the FDA: insufficient evidence for any COVID-19 claim.
CBD is metabolized by the CYP450 enzyme system and can affect the metabolism of other drugs. Some COVID-19 antiviral medications (including Paxlovid) also involve CYP450 pathways. If you are taking any COVID-19 treatment, do not use CBD supplements without first consulting your healthcare provider about potential drug interactions.
A significant difference. Research studies use pharmaceutical-grade CBD with precisely controlled concentrations, purity, and delivery methods. Consumer CBD products vary widely in actual CBD content, bioavailability, formulation, and quality. Even if a specific CBD preparation showed benefit in a human trial, it would not automatically mean that any CBD product available at retail would produce the same effect.
The first half of 2022 brought genuinely interesting CBD and COVID-19 research — most notably the Science Advances study showing CBD's activity against SARS-CoV-2 in cell culture, and continuing preclinical evidence for CBD's anti-inflammatory properties relevant to COVID-19 pathophysiology. This research is scientifically legitimate and worth following.
What it is not, and what it was not described as by its authors, is evidence that CBD treats, prevents, or cures COVID-19 in humans. The gap between a cell culture finding and an approved human therapy is wide and well-defined — filled with the kind of rigorous clinical trial work that had not, as of June 2022, been completed for CBD and COVID-19.
PureCraft CBD will continue to monitor the scientific literature and share honest, contextualized updates as research evolves. In the meantime, explore ourfull product range and view ourthird-party lab results for complete product transparency. These statements have not been evaluated by the FDA. Our products are not intended to diagnose, treat, cure, or prevent any disease.
Medical Disclaimer | Sauna use is contraindicated in certain cardiovascular conditions, pregnancy, and with medications that impair heat tolerance...
Read More
Medical Disclaimer | Cold water immersion is contraindicated in people with cardiovascular conditions, Raynaud's disease, hypertension, or cold ur...
Read More
Medical Disclaimer | This article is for informational and educational purposes only. Intermittent fasting and CBD supplementation should be appro...
Read More